UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 623

Sortiert nach

138 PULMONARY VASCULAR RESPONSES IN UNSEDATED NEWBORN LAMBS

Pediatric research, 1978-04, Vol.12, p.386-386

1978

Link zum Volltext

Verfügbarkeit prüfen

2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism

European heart journal, 2014-11, Vol.35 (43), p.3033-3080

2014

Link zum Volltext

Verfügbarkeit prüfen

3203 – STAT5 ACTIVATION PROMOTES PROGRESSION AND CHEMOTHERAPY-RESISTANCE IN EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Experimental hematology, 2023, Vol.124, p.S151

2023

Link zum Volltext

Verfügbarkeit prüfen

5-Aza-2′-Deoxycytidine Promotes Cytotoxic Effect of CART-Cells on Leukaemia Cells

Blood, 2014-12, Vol.124 (21), p.5812-5812

2014

Link zum Volltext

Verfügbarkeit prüfen

8 Reference materials for the characterization of adeno-associated viral vectors

The CliniBook, 2012, p.83-90

2012

Link zum Volltext

Verfügbarkeit prüfen

921-72 Catheter Management of Stenotic Fontan Baffles & Conduits

Journal of the American College of Cardiology, 1995-02, Vol.25 (2), p.100A-100A

1995

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1175: Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1175-1175

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1611-1611

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1615-1615

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1616: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1616-1616

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1620: In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1620-1620

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1631: Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1631-1631

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1942: The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1942-1942

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2745: AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2745-2745

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2754-2754

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2758-2758

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3038-3038

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3039-3039

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3111: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3111-3111

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3173: Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2018, Vol.78 (13_Supplement), p.3173-3173

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3187: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 2018, Vol.78 (13_Supplement), p.3187-3187

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3276: Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3276-3276

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3839-3839

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3969: Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3969-3969

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4181: The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4181-4181

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 623

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(577)
Mit Volltextzugriff
(581)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(344)
Life Sciences & Biomedicine
(299)
Humans
(260)
Animals
(156)
Mice
(132)
Oncology
(128)
Female
(125)
Hematology
(91)
Xenograft Model Antitumor Assays
(84)
Child
(81)
Pediatrics
(75)
Biological And Medical Sciences
(74)
Cell Line, Tumor
(71)
Mice, Scid
(70)
Medical Sciences
(68)
Male
(66)
Preclinical Testing
(56)
Developmental Therapeutics
(54)
Antineoplastic Agents - Pharmacology
(47)
Precursor Cell Lymphoblastic Leukemia-Lymphoma - Drug Therapy
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

138 PULMONARY VASCULAR RESPONSES IN UNSEDATED NEWBORN LAMBS

2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism

3203 – STAT5 ACTIVATION PROMOTES PROGRESSION AND CHEMOTHERAPY-RESISTANCE IN EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

5-Aza-2′-Deoxycytidine Promotes Cytotoxic Effect of CART-Cells on Leukaemia Cells

8 Reference materials for the characterization of adeno-associated viral vectors

921-72 Catheter Management of Stenotic Fontan Baffles & Conduits

Abstract 1175: Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia

Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting

Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)

Abstract 1616: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program

Abstract 1620: In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia

Abstract 1631: Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia

Abstract 1942: The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia

Abstract 2745: AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104

Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel

Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor

Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia

Abstract 3111: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer

Abstract 3173: Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia

Abstract 3187: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia

Abstract 3276: Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program

Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts

Abstract 3969: Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ)

Abstract 4181: The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

Suchergebnisse filtern